A 510(k) premarket notification clears a medical device for commercial distribution in the United States by demonstrating substantial equivalence to a legally marketed predicate device. Most quality managers understand the predicate comparison at the center of a 510(k) — but many underestimate how much FDA reviewers also scrutinize the quality system and design control documentation behind the device. A technically sound predicate argument can stall or receive a Not Substantially Equivalent (NSE) decision when the underlying QMS documentation does not hold up.

This article covers what FDA expects from a quality management system during and after the 510(k) process, how design controls connect to submission content, and the specific documentation quality teams need to prepare before they file.

What a 510(k) actually is — and what it is not

A 510(k) submission is a premarket notification submitted to FDA’s Center for Devices and Radiological Health (CDRH) under section 510(k) of the Federal Food, Drug, and Cosmetic Act. The submitter asserts that its device is substantially equivalent to one or more predicate devices that were legally marketed before May 28, 1976, or that received 510(k) clearance after that date.

The 510(k) pathway does not require clinical trial data in most cases, but it is not a rubber stamp. FDA reviewers evaluate the technical performance data, intended use comparison, technological characteristics comparison, and increasingly, the software documentation and cybersecurity posture of the device. For combination products, biocompatibility data is reviewed against ISO 10993 standards.

Critically, 510(k) clearance does not substitute for quality system compliance. Cleared devices must be manufactured under a quality system meeting 21 CFR Part 820 (the Quality System Regulation, now updated as the QMSR) before commercial distribution begins. FDA can and does issue warning letters to 510(k)-cleared manufacturers who lack a compliant QMS — clearance and QMS compliance are separate obligations that must both be met.

The QMSR and its connection to 510(k) submissions

On February 2, 2024, FDA’s Quality System Regulation (21 CFR Part 820) was replaced by the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. The QMSR became effective February 2, 2026. Device manufacturers submitting 510(k)s must operate under — or be actively transitioning to — a QMSR-compliant quality system.

The practical effect for 510(k) preparation: design controls under the QMSR closely track ISO 13485 section 7.3, which requires design and development planning, input management, output verification, review processes, validation, and change control documentation. Manufacturers who built design history files (DHFs) under the old 21 CFR Part 820 framework will find the transition largely documentation-structural rather than substantively different, but specific terminology and record organization requirements differ.

FDA does not require you to submit your full quality manual with a 510(k). But reviewers may request quality system records during review, particularly for novel devices, combination products, and software as a medical device (SaMD). The question during preparation is not “will FDA ask for our QMS records?” but “if they do, will those records support clearance?”

Design controls: the QMS foundation of every 510(k)

Design controls are the structured, documented process by which a device design is developed, verified, validated, and transferred to production. Under ISO 13485 section 7.3 and the QMSR, design controls apply to Class II and Class III devices — the device types that typically require 510(k) clearance or PMA approval.

The design history file (DHF) is the organized collection of records that describes the design history of a finished device. It is the primary artifact FDA reviewers and auditors examine to confirm that design controls were followed. A 510(k) submission directly draws on the DHF for performance testing data, specifications, verification and validation (V&V) test results, risk management documentation, and labeling development records.

Design controls require these documented outputs:

• Design and development plan — defines design stages, responsibilities, review schedules, and interfaces between different groups involved in design
• Design inputs — the physical, performance, safety, and regulatory requirements the device must meet, derived from intended use and user needs
• Design outputs — the specifications, drawings, software code, and manufacturing instructions that translate design inputs into a producible device
• Design reviews — formal, documented reviews at defined development stages with participation from people not directly responsible for the design work being reviewed
• Design verification — objective evidence that design outputs meet design inputs (bench testing, analysis, inspection)
• Design validation — objective evidence that a device consistently fulfills user needs and intended uses in the actual or simulated use environment
• Design transfer — documented confirmation that the design can be reproduced using routine production methods
• Design changes — formal change control applied to all modifications made after design freeze, including re-verification and re-validation as required

What 510(k) reviewers look for in QMS-related documentation

FDA’s 510(k) reviewers do not audit the quality system during submission review — that happens during inspections, which may follow clearance. But the technical documentation submitted in a 510(k) must be consistent with a functional quality system. Specific areas where QMS gaps surface in submissions include the following.

Performance testing traceability. Test reports submitted with a 510(k) must trace to design inputs and specifications that are themselves documented in the design controls record. A performance test that cannot be linked to a specific design input creates questions about whether the device was tested against its actual requirements.

Risk management documentation. FDA expects risk management documentation per ISO 14971 for most Class II devices. The risk register and risk management report submitted with or referenced in the 510(k) must reflect risks identified during design — not a risk analysis created after the fact for the submission.

Software documentation. For devices with software, FDA’s guidance on software in medical devices (aligned with IEC 62304) requires a software development lifecycle document, software requirements specifications, verification and validation testing, and anomaly resolution documentation. These documents are generated through design controls. A 510(k) for a software-driven device submitted without this documentation will receive an additional information (AI) request from the reviewer.

Labeling. Device labeling — including instructions for use, indications for use, and contraindications — must be reviewed through design controls. Reviewers compare labeling content to the intended use statement in the 510(k) and to the predicate’s labeling. Inconsistencies between labeling and the intended use statement are a common source of deficiency letters.

QMS readiness checklist for 510(k) preparation

The following checklist addresses the QMS and design control elements that must be in place before a 510(k) submission is filed — and that must be maintained through the clearance review process, which currently averages 177 days for traditional 510(k)s per FDA’s published performance data.

Design and development planning

• Design plan exists and is approved per the organization’s document control procedure
• Design stages, review gates, and responsible parties are defined
• Interfaces between design, engineering, clinical, and regulatory functions are documented

Design inputs

• User needs are documented and approved
• Design inputs are derived from user needs and intended use, not from engineering assumptions alone
• Incomplete, ambiguous, and conflicting inputs were resolved through a documented review
• Applicable standards, regulatory requirements, and customer requirements are captured in inputs

Design outputs

• Specifications, drawings, and manufacturing instructions are version-controlled under document control
• Acceptance criteria exist for each design output
• Outputs essential to safe and proper device function are identified

Design verification and validation

• Verification testing covers each design input requirement with objective pass/fail evidence
• Validation testing uses production-equivalent or production units in actual or simulated use conditions
• Biocompatibility testing references ISO 10993 series, with test reports from qualified labs
• Software V&V is documented per IEC 62304 requirements for the device’s software safety class
• Usability testing is conducted per IEC 62366-1 where required
• Electrical safety and electromagnetic compatibility testing is complete per applicable standards

Risk management

• Risk management file is complete per ISO 14971 — includes hazard identification, risk estimation, risk evaluation, risk controls, and residual risk assessment
• Risk management report is approved and references the risk management plan and file
• Software risks are addressed in the risk management file with linkage to the software risk analysis

Design history file

• DHF index is maintained and current
• All design records are version-controlled, signed, and dated per document control requirements
• DHF is accessible and retrievable without reconstruction

Document control

• All documents submitted with or referenced by the 510(k) are controlled under an approved document control system
• Version history and approval signatures are visible in document headers or metadata
• Any documents that changed during the submission review period have change records

Audit trail and record management

• Electronic records comply with 21 CFR Part 11 if applicable
• Records are retained per applicable regulatory retention requirements

Common QMS gaps found during 510(k) review and post-clearance inspections

FDA’s inspection data and published warning letters point to recurring quality system deficiencies in cleared medical device companies. Understanding the most common gaps helps quality teams prioritize their preparation.

Design inputs that are too vague. Inputs stated as “the device shall be easy to use” or “the device shall perform reliably” cannot be verified or validated. Each input must be specific, measurable, and testable. FDA inspectors cite design control deficiencies most frequently under the design input requirement — it is the most commonly observed design control violation in device inspection reports.

Verification testing done on prototype units. Verification must be performed on representative samples that reflect production processes. Testing done on hand-built prototypes with non-production materials or processes does not constitute valid verification of the production design.

Risk management completed as a paper exercise. Risk analyses that list every imaginable hazard but show no evidence of risk control implementation or post-control risk re-estimation are consistently flagged. FDA expects the risk management process to demonstrably influence the design — risk controls must be traceable to design decisions.

Software documentation missing or incomplete. For software-driven devices, missing IEC 62304 documentation — particularly the software requirements specification, software architecture document, and anomaly list — generates AI requests from CDRH reviewers. This is increasingly common as more devices incorporate software components.

Design changes made after design freeze without formal change control. Post-freeze changes are common and expected. But each change must go through documented change control, including an evaluation of whether the change requires re-verification, re-validation, or regulatory submission of a new or supplemental 510(k). Undocumented changes discovered during post-clearance inspections frequently result in Form 483 audit findings.

Post-clearance QMS obligations

510(k) clearance activates additional QMS obligations that companies must be ready to execute on the day commercial distribution begins.

The complaint handling system must be operational before the first device ships. Every customer complaint must be evaluated to determine whether it constitutes a Medical Device Report (MDR) under 21 CFR Part 803, and MDRs must be submitted to FDA within required timeframes — 30 days for deaths and serious injuries, five days for device malfunctions that caused or could cause serious injury.

Post-market surveillance must be active. For Class II devices, this typically means tracking complaints, service records, and returned products against defined quality metrics. Post-market data feeds into the corrective and preventive action (CAPA) process and, for EU-marketed devices, into the periodic safety update report (PSUR) and post-market clinical follow-up plan under EU MDR.

Device registration and listing must be completed with FDA before commercial distribution. Each establishment involved in the design or manufacture of the device must be registered, and the device must be listed under the applicable 510(k) clearance number.

How an electronic QMS supports 510(k) preparation and post-clearance compliance

Managing a 510(k) submission alongside an active development program is a document-intensive process. Design inputs, outputs, V&V reports, risk management records, and labeling iterations generate hundreds of controlled documents that must remain version-synchronized throughout the review period — which can extend beyond six months.

Cloudtheapp’s platform includes 60+ configurable quality and compliance applications, covering design controls, document management, risk register management, CAPA, complaint handling, and post-market surveillance. The platform’s no-code configurability means quality teams can build a DHF structure that matches their product development workflow, track design input-to-output traceability electronically, and maintain complete audit trails that satisfy both QMSR and ISO 13485 requirements without parallel paper systems.

If your team is preparing a 510(k) submission or building the QMS infrastructure to support post-clearance compliance, request a demo to see how Cloudtheapp supports medical device companies from design controls through commercial distribution.

Conclusion

A 510(k) submission is the front end of a longer regulatory obligation. The predicate comparison gets the device to market; the quality management system keeps it there. Quality managers who treat design controls as a documentation formality — rather than as the operational foundation of the development program — produce submissions that generate deficiency letters and post-clearance inspection findings that require expensive corrective actions.

Building a QMS that genuinely controls the design process, maintains traceable records, and executes post-market obligations from day one of commercial distribution is not a compliance overhead. It is the infrastructure that makes sustained commercial device development possible without regulatory interruption.

]]>